Non-selective beta blockers in cirrhosis: time to extend the indications?

In a cirrhotic patient, irrespective of etiology, the index decompensation represents a critical landmark in their disease progression. Life expectancy plummets with 2-year survival as low as 50% after the development of ascites, which also happens to be the most common decompensating event (1).